Small Cell Lung Cancer Market

DelveInsight’s ‘Small Cell Lung Cancer (SCLC)-Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the SCLC, historical and forecasted epidemiology as well as the SCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

The SCLC market report provides current treatment practices, emerging drugs, SCLC market share of the individual therapies, current and forecasted SCLC market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current SCLC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Small Cell Lung Cancer Disease Understanding and Treatment Algorithm

Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC, the more common). The treatment method is different for both types.

SCLC spreads (metastasizes) much faster than NSCLC to other organs, whereas microscopically, SCLC is composed of much smaller cells. SCLC can be fatal in a few weeks if untreated, in contrast to most cases of NSCLC. Also, NSCLC accounts for about 80–85% of lung cancers.

SCLC is an aggressive disease with distinct pathological, clinical, and molecular characteristics along with having a high metastatic potential that results in clinically poor prognosis, which is not the case for NSCLC. SCLC is also known as ‘oat-cell’ cancer because the cells look like oats under the microscope. It often starts in the bronchi, then quickly grows and spread to other parts of the body, including the lymph nodes. This type of lung cancer represents about 15% of lung cancers and is typically caused by tobacco smoking. SCLC tends to spread quite early and it can also be classed as neuroendocrine tumors.


Diagnosis 

The diagnosis of cancer mainly starts with a different set of tests that can be performed to examine cancer or for its better and effective treatment. They may start off by examining the extent of cancer metastasis, which can be done by analyzing what other parts of the body are affected apart from the point of initiation. For example, imaging tests—that displays the internal picture of the body—can indicate if cancer has spread, but they can never be used alone to diagnose SCLC.

A biopsy is recommended as it the only way for the doctor to confirm the presence of cancer; however, there are other methods also, if biopsy cannot be performed.

The doctor may consider these factors when choosing a diagnostic test:

  • Size, location, and type of cancer suspected
  • Signs and symptoms
  • Age and general health
  • The results of earlier medical tests


Treatment 

It covers the details of conventional and current medical therapies available in the Small Cell Lung Cancer market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.

The DelveInsight Small Cell Lung Cancer market report gives a thorough understanding of Small Cell Lung Cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Small Cell Lung Cancer treatment algorithms and treatment guidelines for Small Cell Lung Cancer in the US, Europe, and Japan.


Small Cell Lung Cancer Epidemiology  

The Small Cell Lung Cancer epidemiology division provide insights about historical and current Small Cell Lung Cancer patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Key Findings

The total incident cases of SCLC patients were found to be more in males than in females in 7MM during the study period i.e. 2017–2030.

The disease epidemiology covered in the report provides historical as well as forecasted Small Cell Lung Cancer epidemiology [segmented as Total Incident Patient Population, Gender-specific Incident Patient Population, Age-specific Incident Patient Population, Stage-Specific Incident Population, and Line-wise Treatment of Extensive-Stage SCLC] scenario of Small Cell Lung Cancer in 7MM covering United States, EU5 countries (Germany, France, Italy , Spain, and United Kingdom), and Japan from 2017 to 2030.


Country Wise- Small Cell Lung Cancer Epidemiology 

The epidemiology segment also provides the Small Cell Lung Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 


Small Cell Lung Cancer Drug Chapters

Drug chapter segment of the Small Cell Lung Cancer report encloses the detailed analysis of Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Small Cell Lung Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Marketed Drugs 

Opdivo (Nivolumab): Bristol-Myers Squibb

Opdivo (Nivolumab) by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. It is a prescription medicine used to treat people with unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), advanced renal cell carcinoma, classical hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer and hepatocellular carcinoma. It is not known if Opdivo is safe and effective in children younger than 18 years of age. This drug is approved under accelerated approval based on overall response rate and duration of response for patients with metastatic small cell lung cancer with progression after platinum-based chemotherapy and at least one other line of therapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Keytruda (Pembrolizumab): Merck

Keytruda, also known as pembrolizumab, is a programmed death receptor-1 (PD-1)-blocking antibody. It is mainly used for cancers that are advanced, have spread to other parts of the body (metastatic) or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high levels of a protein known as PD-L1. This drug is also used to help prevent the cancer from coming back after patients had surgery to remove melanoma (adjuvant therapy).

Products detail in the report…


Small Cell Lung Cancer Emerging Drugs 

Imfinzi +/- tremelimumab: AstraZeneca

Imfinzi (Durvalumab) also known as medi4736 with or without tremelimumab, is under development by AstraZeneca. It is administered intravenously after completing a combination of chemotherapy and radiation therapy (CRT) given at the same time, also known as concurrent CRT. Imfinzi may also attack healthy cells. It binds to a protein called PD-L1, which is found on some cancer cells and may block this protein and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor.

Lurbinectedin (PM01183): PharmaMar

Lurbinectedin (Zepsyre, PM1183) by PharmaMar, is a compound in clinical research that belongs to the RNA polymerase II enzyme inhibitors family, which is essential for the transcription process. By inhibiting transcription, the compound reduces the expression of certain factors that are involved in tumor progression and blocks the DNA repair system called NER. This eventually induces the death of tumor cells. The antitumor efficacy of PM1183 (lurbinectedin) is being investigated in several types of tumors. Currently it is in phase III clinical developmental trial for SCLC.

RRx-001: EpicentRx

EpicentRx is developing its lead program RRx-001, which is among a portfolio of immunotherapeutic compounds that normalize the tumor microenvironment, activate the tumor associated macrophages (TAMs) of the innate immune system, and sensitize solid tumors to standard therapies in small cell lung cancer (SCLC), glioblastoma, colorectal cancer and additional cancers. It is a next generation, small molecule anticancer immunotherapeutic that down regulates the CD47/SIRPα axis and repolarizes TAMs and other immunosuppressive cells in the tumor microenvironment to an immunostimulatory phenotype. RRx-001 is designed to be used either as a monotherapy or in combination with chemotherapy, radiation therapy or immunotherapy. It has been granted Orphan Drug Designation from the US FDA and EMA for the treatment of patients with small cell lung cancer.

Products detail in the report…


Small Cell Lung Cancer Market Outlook

The Small Cell Lung Cancer market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Small Cell Lung Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of Small Cell Lung Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017–2030. The therapeutic market of Small Cell Lung Cancer in seven major markets is expected to generate USD 444 million in 2017 and will increase in the study period 2017–2030.


Key Findings

This section includes a glimpse of the Small Cell Lung Cancer market in 7MM.


The United States Market Outlook

This section provides the total Small Cell Lung Cancer market size and market size by therapies in the United States.


EU-5 Countries: Market Outlook

The total Small Cell Lung Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.


Japan Market Outlook 

The total Small Cell Lung Cancer market size and market size by therapies in Japan is also mentioned. 


Small Cell Lung Cancer Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Small Cell Lung Cancer market or expected to get launched in the market during the study period 2017-2030. The analysis covers Small Cell Lung Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.    

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Small Cell Lung Cancer Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Small Cell Lung Cancer key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Small Cell Lung Cancer emerging therapies.


Reimbursement Scenario in Small Cell Lung Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 


KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Small Cell Lung Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Small Cell Lung Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 


Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Small Cell Lung Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.


Scope of the Report

  • The report covers the descriptive overview of Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Small Cell Lung Cancer epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Small Cell Lung Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Small Cell Lung Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Small Cell Lung Cancer market


Report Highlights

  • In the coming years, Small Cell Lung Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Small Cell Lung Cancer. Launch of emerging therapies will significantly impact the Small Cell Lung Cancer market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Small Cell Lung Cancer
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Small Cell Lung Cancer Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Small Cell Lung Cancer Pipeline Analysis
  • Small Cell Lung Cancer Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Small Cell Lung Cancer Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Small Cell Lung Cancer Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Small Cell Lung Cancer Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Small Cell Lung Cancer market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Small Cell Lung Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Small Cell Lung Cancer market size during the forecast period (2017-2030)?
  • At what CAGR, the Small Cell Lung Cancer market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Small Cell Lung Cancer market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Small Cell Lung Cancer market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Small Cell Lung Cancer?
  • What is the historical Small Cell Lung Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Small Cell Lung Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Small Cell Lung Cancer?
  • Out of all 7MM countries, which country would have the highest prevalent population of Small Cell Lung Cancer during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Small Cell Lung Cancer treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Small Cell Lung Cancer in the USA, Europe, and Japan?
  • What are the Small Cell Lung Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Small Cell Lung Cancer?
  • How many therapies are developed by each company for Small Cell Lung Cancer treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Small Cell Lung Cancer treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Small Cell Lung Cancer therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Small Cell Lung Cancer and their status?
  • What are the key designations that have been granted for the emerging therapies for Small Cell Lung Cancer?
  • What are the global historical and forecasted market of Small Cell Lung Cancer?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Small Cell Lung Cancer market
  • To understand the future market competition in the Small Cell Lung Cancer market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Small Cell Lung Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Small Cell Lung Cancer market
  • To understand the future market competition in the Small Cell Lung Cancer market


What is Small Cell Lung Cancer?

Small Cell Lung Cancer is a fast growing lung cancer. It usually starts in bronchi (center of the chest). Though the cancer cells are small, but they grow aggressively and create large tumors. These kind of tumors often metastasize quickly to other parts of the body


What is forecasted Small Cell Lung Cancer market size in 2030?

Small Cell Lung Cancer Market Size is Expected to Increase at a CAGR of 13.2% for the Study Period (2017-2030) in the 7MM


Which geography had the highest Small Cell Lung Cancer market size in 2017?

Among 7MM countries, the United States had the highest market size of Small Cell Lung Cancer in 2017 that accounts for approximately 48% of the total market


How is epidemiology segmented for Small Cell Lung Cancer?

The Small Cell Lung Cancer (SCLC) Epidemiology segmentation is based on Total Incident Patient Population, Gender-specific, Stage-specific, Age-specific, and Line-wise treatment of extensive-stage SCLC


Which companies are developing drugs for Small Cell Lung Cancer?

AstraZeneca, PharmaMar, EpicentRx, United Therapeutics, Ipsen, G1 Therapeutics, Otsuka Holdings, Takeda are developing drugs for Small Cell Lung Cancer

1.   Key Insights

2.   Executive Summary of SCLC

3.   SWOT Analysis for SCLC

4.   SCLC: Market Overview at a Glance

4.1.    Total Market Share (%) Distribution of SCLC in 2017

4.2.    Total Market Share (%) Distribution of SCLC in 2030

5.   Small Cell Lung Cancer (SCLC): Disease Background and Overview

5.1. Introduction

5.1.1. Signs and Symptoms of Lung Cancer

5.1.2. Risk Factors of SCLC

5.1.3. Causes of SCLC

5.1.4. Disease Biology: SCLC

5.2. Diagnosis of Small-cell Lung Cancer (SCLC)

5.2.1. Imaging tests

5.2.2. Staging in SCLC

6.   Epidemiology and Patient Population

6.1.    Epidemiology Key Findings

6.2.    Assumptions and Rationale: 7MM

6.3.    Total Incidence of Lung Cancer in the 7MM

6.4.    Total Incidence cases of SCLC in the 7MM

7.   United States

7.1.    Total Incidence cases of SCLC in the United States

7.2.    Gender-specific Incidence of SCLC in the United States

7.3.    Age-specific Incidence of SCLC in the United States

7.4.    Stage-Specific Incidence of SCLC in the United States

7.5.    Line-wise Treatment of Extensive-Stage SCLC in the United States

8.   EU-5 Country-wise Epidemiology

8.1. Germany

8.1.1. Total Incidence cases of SCLC in Germany

8.1.2. Gender-specific Incidence of SCLC in Germany

8.1.3. Age-specific Incidence of SCLC in Germany

8.1.4. Stage-Specific Incidence of SCLC in Germany

8.1.5. Line-wise Treatment of Extensive-Stage SCLC in Germany

8.2. France

8.2.1. Total Incidence cases of SCLC in France

8.2.2. Gender-specific Incidence of SCLC in France

8.2.3. Age-specific Incidence of SCLC in France

8.2.4. Stage-Specific Incidence of SCLC in France

8.2.5. Line-wise Treatment of Extensive-Stage SCLC in France

8.3. Italy

8.3.1. Total Incidence cases of SCLC in Italy

8.3.2. Gender-specific Incidence of SCLC in Italy

8.3.3. Age-specific Incidence of SCLC in Italy

8.3.4. Stage-Specific Incidence of SCLC in Italy

8.3.5. Line-wise Treatment of Extensive-Stage SCLC in Italy

8.4. Spain

8.4.1. Total Incidence cases of SCLC in Spain

8.4.2. Gender-specific Incidence of SCLC in Spain

8.4.3. Age-specific Incidence of SCLC in Spain

8.4.4. Stage-Specific Incidence of SCLC in Spain

8.4.5. Line-wise Treatment of Extensive-Stage SCLC in Spain

8.5. United Kingdom

8.5.1. Total Incidence cases of SCLC in the United Kingdom

8.5.2. Gender-specific Incidence of SCLC in the United Kingdom

8.5.3. Age-specific Incidence of SCLC in the United Kingdom

8.5.4. Stage-Specific Incidence of SCLC in the United Kingdom

8.5.5. Line-wise Treatment of Extensive-Stage SCLC in the United Kingdom

9.   Japan

9.1.    Total Incidence cases of SCLC in Japan

9.2.    Gender-specific Incidence of SCLC in Japan

9.3.    Age-specific Incidence of SCLC in Japan

9.4.    Stage-Specific Incidence of SCLC in Japan

9.5.    Line-wise Treatment of Extensive-Stage SCLC in Japan

10. Current Treatment Practices for Small-cell Lung Cancer (SCLC)

10.1. Management Algorithm of SCLC

10.2. SCLC Treatment Paradigm

10.3. Radiation Therapy

10.4. Surgery

10.5. Metastatic Lung Cancer

10.6. Remission and the Chance of Recurrence

10.7.  Guidelines for SCLC

10.7.1.     Treatment Differences across 7MM

10.7.2.     ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

10.7.3.     The American College of Chest Physicians (ACCP) Clinical Practice Guidelines: SCLC

11. Patient Journey

12. Unmet Needs

13. Key Endpoints in SCLC Clinical Trials

14. Marketed Products

14.1.             Opdivo (Nivolumab): Bristol-Myers Squibb/ Ono Pharmaceutical

14.1.1.     Product Description

14.1.2.     Regulatory Milestones

14.1.3.     Other Developmental Activities

14.1.4.     Pivotal Clinical Trials

14.1.5.     Ongoing Clinical Trials Information

14.1.6.     Safety and Efficacy of ongoing trials

14.2.             Keytruda (Pembrolizumab): Merck

14.2.1.     Product Description

14.2.2.     Regulatory Milestones

14.2.3.     Other Developmental Activities

14.2.4.     Pivotal Clinical Trials

14.2.5.     Ongoing Clinical Trials Information

14.2.6.     Safety and Efficacy of Ongoing Trials

14.3.             Tecentriq (Atezolizumab): Hoffmann-La Roche

14.3.1.     Product Description

14.3.2.     Regulatory Milestones

14.3.3.     Other Developmental Activities

14.3.4.     Pivotal Clinical Trials

14.3.5.     Ongoing Clinical Trials Information

14.3.6.     Safety and Efficacy of Ongoing Clinical Trials

15. Emerging Therapies

15.1.             Key Cross

15.2.             Imfinzi +/- tremelimumab: AstraZeneca

15.2.1.     Product Description

15.2.2.     Other Developmental Activities

15.2.3.     Clinical Development

15.2.4.     Safety and Efficacy

15.3.             Lurbinectedin (PM01183): PharmaMar

15.3.1.     Product Description

15.3.2.     Other Developmental Activities

15.3.3.     Clinical Development

15.3.4.     Safety and Efficacy

15.4.             RRx-001: EpicentRx

15.4.1.     Product Description

15.4.2.     Other Developmental Activities

15.4.3.     Clinical Development

15.4.4.     Safety and Efficacy

15.5.             Dinutuximab (Unituxin): United Therapeutics

15.5.1.     Product Description

15.5.2.     Other Developmental Activities

15.5.3.     Clinical Development

15.5.4.     Safety and Efficacy

15.6.             Irinotecan liposome injection: Ipsen

15.6.1.     Product Description

15.6.2.     Other Developmental Activities

15.6.3.     Clinical Development

15.6.4.     Safety and Efficacy

15.7.             Trilaciclib (G1T28): G1 Therapeutics

15.7.1.     Product Description

15.7.2.     Other Developmental Activities

15.7.3.     Clinical Development

15.7.4.     Safety and Efficacy

15.8.             Dendritic Cell-based p53 Vaccine + Nivolumab + Ipilimumab: MultiVir

15.8.1.     Product Description

15.8.2.     Other Developmental Activities

15.8.3.     Clinical Development

15.8.4.     Safety and Efficacy

15.9.             Guadecitabine + Carboplatin: Otsuka Holdings

15.9.1.     Product Description

15.9.2.     Other Developmental Activities

15.9.3.     Clinical Development

15.10.          Iclusig (ponatinib): Takeda

15.10.1. Product Description

15.10.2. Other Developmental Activities

15.10.3. Clinical Development

15.10.4. Safety and Efficacy

16. Conjoint Analysis of Small Cell Lung Cancer (SCLC) Therapies

17. Small Cell Lung Cancer (SCLC): Seven Major Market Analysis

17.1. Key Findings

17.2. Market Outlook: 7MM

17.3. Total Market Size of SCLC in the 7MM

17.4. Market Size of SCLC by Therapeutic Class in the 7MM

18. United States Market Size

18.1. Total Market size of SCLC in the United States

19. EU-5 Market Size

19.1.             Germany Market Size

19.1.1.     Total Market size of SCLC in Germany

19.2.             France Market Size

19.2.1.     Total Market size of SCLC in France

19.3.             Italy Market Size

19.3.1.     Total Market size of SCLC in Italy

19.4.             Spain Market Size

19.4.1.     Total Market size of SCLC in Spain

19.5.             United Kingdom Market Size

19.5.1.     Total Market size of SCLC in the United Kingdom

20. Japan Market Size

20.1. Total Market size of SCLC in Japan

21. Market Access and Reimbursement Scenario of SCLC Therapies

22. Market Drivers

23. Market Barriers

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. Disclaimer

26. DelveInsight Capabilities

27. About DelveInsight

Table 1 Summary of Small-cell Lung Cancer (SCLC) Market, Epidemiology, and Key Events (2017–2030)

Table 2 Molecular Aberrations of SCLC

Table 3 TNM Staging of SCLC

Table 4 Major Sources Used

Table 5 Total Incidence of Lung Cancer in the 7MM (2017–2030)

Table 6 Total Incidence cases of SCLC in the 7MM (2017–2030)

Table 7 Total Incidence cases of SCLC in the United States (2017–2030)

Table 8 Gender-specific Incidence of SCLC in the United States (2017–2030)

Table 9 Age-specific Incidence of SCLC in the United States (2017–2030)

Table 10 Stage-Specific Incidence of SCLC in the United States (2017–2030)

Table 11 Line-wise Treatment of Extensive-Stage SCLC in the United States (2017-2030)

Table 12 Total Incidence cases of SCLC in Germany (2017–2030)

Table 13 Gender-specific Incidence of SCLC in Germany (2017–2030)

Table 14 Age-specific Incidence of SCLC in Germany (2017–2030)

Table 15 Stage-Specific Incidence of SCLC in Germany (2017–2030)

Table 16 Line-wise Treatment of Extensive-Stage SCLC in Germany (2017–2030)

Table 17 Total Incidence cases of SCLC in France (2017–2030)

Table 18 Gender-specific Incidence of SCLC in France (2017–2030)

Table 19 Age-specific Incidence of SCLC in France (2017–2030)

Table 20 Stage-Specific Incidence of SCLC in France (2017–2030)

Table 21 Line-wise Treatment of Extensive-Stage SCLC in France (2017–2030)

Table 22 Total Incidence cases of SCLC in Italy (2017–2030)

Table 23 Gender-specific Incidence of SCLC in Italy (2017–2030)

Table 24 Age-specific Incidence of SCLC in Italy (2017–2030)

Table 25 Stage-Specific Incidence of SCLC in Italy (2017–2030)

Table 26 Line-wise Treatment of Extensive-Stage SCLC in Italy (2017–2030)

Table 27 Total Incidence cases of SCLC in Spain (2017–2030)

Table 28 Gender-specific Incidence of SCLC in Spain (2017–2030)

Table 29 Age-specific Incidence of SCLC in Spain (2017–2030)

Table 30 Stage-Specific Incidence of SCLC in Spain (2017–2030)

Table 31 Line-wise Treatment of Extensive-Stage SCLC in Spain (2017–2030)

Table 32 Total Incidence cases of SCLC in the United Kingdom (2017–2030)

Table 33 Gender-specific Incidence of SCLC in the United Kingdom (2017–2030)

Table 34 Age-specific Incidence of SCLC in the United Kingdom (2017–2030)

Table 35 Stage-Specific Incidence of SCLC in the United Kingdom (2017–2030)

Table 36 Line-wise Treatment of Extensive-Stage SCLC in in the United Kingdom (2017–2030)

Table 37 Total Incidence cases of SCLC in Japan (2017–2030)

Table 38 Age-specific Incidence of SCLC in Japan (2017–2030)

Table 39 Age-specific Incidence of SCLC in Japan (2017–2030)

Table 40 Stage-Specific Incidence of SCLC in Japan (2017–2030)

Table 41 Line-wise Treatment of Extensive-Stage SCLC in Japan (2017–2030)

Table 42 ASCO Key Recommendations for Treatment of SCLC

Table 43 Opdivo (Nivolumab), Clinical Trial Description

Table 44 Keytruda, Clinical Trial Description 2020

Table 45 Tecentriq, Clinical Trial Description, 2020

Table 46 Emerging Drugs Key-cross Competition

Table 47 Imfinzi +/- tremelimumab , Clinical Trial Description, 2020

Table 48 Lurbinectedin (PM01183), Clinical Trial Description, 2020

Table 49 RRx-001 , Clinical Trial Description, 2020

Table 50 Dinutuximab (Unituxin), Clinical Trial Description, 2020

Table 51 Irinotecan liposome injection, Clinical Trial Description, 2020

Table 52 Trilaciclib (G1T28), Clinical Trial Description, 2020

Table 53 Dendritic Cell based p53 Vaccine + Nivolumab + Ipilimumab, Clinical Trial Description, 2020

Table 54 Guadecitabine, Clinical Trial Description, 2020

Table 55 Iclusig (ponatinib), Clinical Trial Description, 2020

Table 56 List of Marketed Products with their respective Therapeutic Classes

Table 57 7MM Market Size of SCLC in USD Million (2017–2030)

Table 58 7MM Market Size of SCLC By Line of Therapy in USD Million (2017–2030)

Table 59 US Market Size of SCLC By Line of Therapy in USD Million (2017–2030)

Table 60 Germany Market Size of SCLC By Line of Therapy in USD Million (2017–2030)

Table 61 France Market Size of SCLC By Line of Therapy in USD Million (2017–2030)

Table 62 Italy Market Size of SCLC By Line of Therapy in USD Million (2017–2030)

Table 63 Spain Market Size of SCLC By Line of Therapy in USD Million (2017–2030)

Table 64 United Kingdom Market Size of SCLC By Line of Therapy in USD Million, (2017–2030)

Table 65 Japan Market Size of SCLC By Line of Therapy in USD Million (2017–2030)

Figure 1 SCLC SWOT Analysis

Figure 2 Some of the Areas for Current Therapeutic Interest in SCLC

Figure 3 Sign and Symptoms of SCLC

Figure 4 Risks Factors of SCLC

Figure 5 Imaging Tests for SCLC

Figure 6 Stages of SCLC

Figure 7 Global Heat Map of Lung Cancer

Figure 8 Total Incidence of Lung Cancer in the 7MM (2017–2030)

Figure 9 Total Incidence cases of SCLC in the 7MM (2017–2030)

Figure 10 Total Incidence cases of SCLC in the United States (2017–2030)

Figure 11 Gender-specific Incidence of SCLC in the United States (2017–2030)

Figure 12 Age-specific Incidence of SCLC in the United States (2017–2030)

Figure 13 Stage-Specific Incidence of SCLC in the United States (2017–2030)

Figure 14 Line-wise Treatment of Extensive-Stage SCLC in the United States (2017–2030)

Figure 15 Total Incidence cases of SCLC in Germany (2017–2030)

Figure 16 Gender-specific Incidence of SCLC in Germany (2017–2030)

Figure 17 Age-specific Incidence of SCLC in Germany (2017–2030)

Figure 18 Stage-Specific Incidence of SCLC in Germany (2017–2030)

Figure 19 Line-wise Treatment of Extensive-Stage SCLC in Germany (2017–2030)

Figure 20 Total Incidence cases of SCLC in France (2017–2030)

Figure 21 Gender-specific Incidence of SCLC in France (2017–2030)

Figure 22 Age-specific Incidence of SCLC in France (2017–2030)

Figure 23 Stage-Specific Incidence of SCLC in France (2017–2030)

Figure 24 Line-wise Treatment of Extensive-Stage SCLC in France (2017–2030)

Figure 25 Total Incidence cases of SCLC in Italy (2017–2030)

Figure 26 Gender-specific Incidence of SCLC in Italy (2017–2030)

Figure 27 Age-specific Incidence of SCLC in Italy (2017–2030)

Figure 28 Stage-Specific Incidence of SCLC in Italy (2017–2030)

Figure 29 Line-wise Treatment of Extensive-Stage SCLC in Italy (2017–2030)

Figure 30 Total Incidence cases of SCLC in Spain (2017–2030)

Figure 31 Gender-specific Incidence of SCLC in Spain (2017–2030)

Figure 32 Age-specific Incidence of SCLC in Spain (2017–2030)

Figure 33 Stage-Specific Incidence of SCLC in Spain (2017–2030)

Figure 34 Line-wise Treatment of Extensive-Stage SCLC in Spain (2017–2030)

Figure 35 Total Incidence cases of SCLC in the United Kingdom (2017–2030)

Figure 36 Gender-specific Incidence of SCLC in the United Kingdom (2017–2030)

Figure 37 Age-specific Incidence of SCLC in the United Kingdom (2017–2030)

Figure 38 Stage-Specific Incidence of SCLC in the United Kingdom (2017–2030)

Figure 39 Line-wise Treatment of Extensive-Stage SCLC in in the United Kingdom (2017–2030)

Figure 40 Total Incidence cases of SCLC in Japan (2017–2030)

Figure 41 Gender-specific Incidence of SCLC in Japan (2017–2030)

Figure 42 Age-specific Incidence of SCLC in Japan (2017–2030)

Figure 43 Stage-Specific Incidence of SCLC in Japan (2017–2030)

Figure 44 Line-wise Treatment of Extensive-Stage SCLC in Japan (2017–2030)

Figure 45 Initial Management Algorithm of SCLC

Figure 46 Management of Relapsed/Refractory SCLC

Figure 47 SCLC Treatment Algorithm by ESMO

Figure 48 Unmet Needs of SCLC

Figure 49 Market Size of SCLC in the 7MM Countries in USD Million (2017–2030)

Figure 50 Market Size of SCLC by Line of therapies in the 7MM, in USD Million (2017–2030)

Figure 51 Market Size of SCLC in the US, USD Millions (2017–2030)

Figure 52 Market Size of SCLC in Germany, USD Millions (2017–2030)

Figure 53 Market Size of SCLC in France, USD Millions (2017–2030)

Figure 54 Market Size of SCLC in Italy, USD Millions (2017–2030)

Figure 55 Market Size of SCLC in Spain, USD Millions (2017–2030)

Figure 56 Market Size of SCLC in the United Kingdom USD Millions (2017–2030)

Figure 57 Market Size of SCLC in Japan, USD Millions (2017–2030)

Figure 58 Market Drivers of SCLC

Figure 59 Market Barriers of SCLC

  • Tags:
  • Small Cell Lung Cancer market
  • Small Cell Lung Cancer market resea...
  • Small Cell Lung Cancer market insig...
  • Small Cell Lung Cancer market trend...
  • Small Cell Lung Cancer market forec...
  • Small Cell Lung Cancer market share
  • Small Cell Lung Cancer pipeline dru...
  • Small Cell Lung Cancer treatment al...
  • Small Cell Lung Cancer drugs
  • Small Cell Lung Cancer sales foreca...
  • Small Cell Lung Cancer market size
  • Small Cell Lung Cancer disease
  • Small Cell Lung Cancer epidemiology
  • Small Cell Lung Cancer

Forward to Friend

Need A Quote